Pharmaceutical industry
Immunex Corporation and The Johns Hopkins University School of Medicine have entered into a three-year research collaboration to develop controlled-release formulations of yeast-derived granulocyte-macrophage colony stimulating factor (GM-CSF) to be used in conjunction with tumor vaccine adjuvants. The collaboration will focus on evaluating the clinical safety and efficacy of GM-CSF
Pharmaceutical industry
ImmunoGen, Inc., a biopharmaceutical company focused on cancer treatment, has been awarded a $750,000 Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) to develop targeted small-molecule drugs for cancer treatment. The grant will fund the company's research on immunoconjugates, a class
Pharmaceutical industry
Dr. Francis P. Tally, a renowned infectious disease expert with 23 years of research experience, has been appointed Vice President, Research and Development at Cubist Pharmaceuticals. Previously, Dr. Tally was Executive Director of Infectious Disease, Molecular Biology and Natural Products Research at Lederle Laboratories. He brings a unique clinical perspective
Pharmaceutical industry
U.S. Bioscience Inc. has announced the first introduction for sale of Ethyol(R), a selective cytoprotective agent, in Germany, with plans to launch in the United Kingdom soon. This move follows the European Union's Committee for Proprietary Medicinal Products' recommendation for approval in September 1994, and
Pharmaceutical industry
ImClone Systems Incorporated, a biopharmaceutical company specializing in cancer treatment and related disorders, has released its 1994 financial results. Despite a net loss, the company showed promising revenue growth and a significant decrease in operating expenses. Key Takeaways: * The company reported revenues of $950,000 for the year ended December
Pharmaceutical industry
Zila, Inc. has announced a significant milestone in the global expansion of its oral cancer diagnostic, OraScan. A European and Australian licensing and distribution agreement has been signed with Block Drug Company, Inc., a U.S. Fortune 500 company. This agreement paves the way for the introduction of OraScan in
Pharmaceutical industry
Chiron Corp., a biotechnology company headquartered in Emeryville, California, has announced the acquisition of exclusive rights to Cerubidine (daunorubicin hydrochloride) for injection, a chemotherapeutic product for the treatment of certain leukemias. The company has partnered with Ben Venue Laboratories to manufacture and distribute the product, which will be sold under
